Infection, Bacterial

0
Pipeline Programs
2
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Alliance Pharmaceuticals
1 program
Optimised kangaroo careN/A1 trial
Active Trials
NCT05993442Recruiting3,080Est. Mar 2026

Trial Timeline

Clinical trial activity over time

2024
2025
2026
Alliance PharmaceuticalsOptimised kangaroo care

Clinical Trials (1)

Total enrollment: 3,080 patients across 1 trials

Optimising Kangaroo Care to Reduce Neonatal Severe Infection/Sepsis and Resistant Bacterial Colonisation Among High-risk Infants in NICU.

Start: May 2024Est. completion: Mar 20263,080 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 3,080 patients
2 companies competing in this space